deferoxamine infusion test
Jump to navigation
Jump to search
Indications
- alumininum toxicity, serum aluminum > 60 ng/mL (prior to dialysis)
Procedure
- infusion of 5 mg/kg of desferoxamine IV over 20 minutes or more post dialysis
- an increase in serum aluminum > 150 ng/mL with sample prior to next dialysis session
More general terms
Additional terms
References
- ↑ Milliner DS et al Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy. Ann Intern Med. 1984 Dec;101(6):775-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/6208838
- ↑ DESFERAL: Novartis Pharmaceuticals http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20(General%20Monographs-%20D)/DESFERAL.html